Objectives: To update the EULAR recommendations for management of knee osteoarthritis (OA)
by an evidence based medicine and expert opinion approach. Methods: The literature …

Objective: To develop evidence based recommendations for the management of hip
osteoarthritis (OA). Methods: The multidisciplinary guideline development group comprised 18 …

OBJECTIVE: A survey was performed in 5 European countries (France, Germany, Italy,
Portugal, and Spain) to estimate the prevalence of fibromyalgia (FM) in the general population. …

Objectives To evaluate the prevalence and type of rheumatic immune-related adverse events
(irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as the correlation …

Low-dose pulse methotrexate has emerged as one of the most frequently used slow-acting,
symptom-modifying antirheumatic drugs in patients with rheumatoid arthritis (RA) because of …

Methotrexate has been approved for the treatment of refractory rheumatoid arthritis by several
regulatory agencies, including the Food and Drug Administration. The tendency is now to …

OBJECTIVE: To estimate the prevalence of fibromyalgia (FM) syndrome in the French
general population. METHODS: A validated French version of the London Fibromyalgia …

It is unanimously accepted that there is an unmet need for pain medications that are both
effective and safe. Unfortunately, no really novel analgesics have been approved over the past …

Anti-drug antibodies (ADAbs) develop in up to a third of patients treated with biologic agents,
with such immunogenicity being one of the main reasons for the loss of efficacy observed in …

Background: Adverse drug events (ADEs) are a substantial cause of hospital admissions.
However, little is known about the incidence, preventability and severity of ADEs resulting in …